WHWK — Whitehawk Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2018-06-26.
Performance
Technicals
Others in Healthcare
Measured signals that fired on WHWK
| date | signal | measured base rate |
|---|---|---|
| 2026-07-16 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-06-26 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
| 2026-06-09 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-05-15 | Institutional holders jumped in a quarter ownership | -0.52% over 21 days · t = -0.38 · n = 1,553 not distinguishable from its control group |
| 2026-04-17 | Cluster sale: three or more insiders insider | -0.36% over 21 days · t = -3.35 · n = 21,529 statistically distinguishable from its control group |
| 2026-03-10 | Cluster sale: three or more insiders insider | -0.36% over 21 days · t = -3.35 · n = 21,529 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-05-14 | Dalal Anupam Director | Grant or award | 1.3M | 3.92 | 5.0M |
| 2026-05-14 | Castelein Caley Director | Grant or award | 255.1K | 3.92 | 1,000.0K |
| 2026-05-14 | Lennon David James CHIEF EXECUTIVE OFFICER | Grant or award | 51.0K | 3.92 | 200.0K |
| 2026-05-14 | BALL BRYAN See remarks | Grant or award | 51.0K | 3.92 | 200.0K |
| 2026-05-14 | Giacobello Scott M. CHIEF FINANCIAL OFFICER | Grant or award | 38.3K | 3.92 | 150.0K |
| 2026-05-14 | Dugan Margaret Chief Medical Officer | Grant or award | 19.1K | 3.92 | 75.0K |
| 2026-04-16 | Giacobello Scott M. CHIEF FINANCIAL OFFICER | Open-market sale | 141.6K | 4.13 | 584.8K |
| 2026-04-15 | Giacobello Scott M. CHIEF FINANCIAL OFFICER | Open-market sale | 77.0K | 3.86 | 297.2K |
| 2026-04-14 | BALL BRYAN See remarks | Open-market sale | 92.5K | 3.64 | 336.6K |
| 2026-04-13 | BALL BRYAN See remarks | Open-market sale | 26.4K | 3.46 | 91.3K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| QVT Financial LP | 15.9M | 4.6M |
| ORBIMED ADVISORS LLC | 14.4M | 4.2M |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 12.8M | 3.7M |
| ACUTA CAPITAL PARTNERS, LLC | 11.8M | 3.4M |
| Avoro Capital Advisors LLC | 9.8M | 2.8M |
| KVP Capital Advisors, LP | 7.5M | 2.2M |
| Siren, L.L.C. | 7.2M | 2.1M |
| Yu Fan | 7.1M | 2.1M |
| STEMPOINT CAPITAL LP | 6.5M | 1.9M |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.5M | 1.3M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| 10-Q | 2026-08-06 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-06 | 2026-08-06 | on EDGAR ↗ |
| 4 | 2026-07-30 | 2026-05-14 | on EDGAR ↗ |
| 4 | 2026-06-15 | 2026-06-12 | on EDGAR ↗ |
| 4 | 2026-06-15 | 2026-06-12 | on EDGAR ↗ |
| 4 | 2026-06-15 | 2026-06-12 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about WHWK
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →